| | Author | Interventions | Control group | The number of cases/case | Gender (male/female) | Age | Period of treatment (d) | Diagnostic criteria and efficacy criteria | Outcome indicators | Follow-up time | Region | | Experimental group | Control group | | | |
| | Zhang 2017 [8] | ⑩ | ① + ② | 50 | 50 | 63/37 | 18–60 | 56 | (1), (2) | Symptom score (cough score, sputum score, diaphragmatic fullness score), lung function (PEF, FVC, FEV1), total effective rate, adverse reactions | Not mentioned | China’s Hebei province |
| | Zheng 2014 [9] | ⑩ + ③ | ③ | 40 | 40 | 57/62 | 15–67 | 10 d | (1), (3) | Total response rate, lung function (FVC, FEV1, PEF), general adaptive quality of life questionnaire dimensions and total scores, specific quality of life questionnaire scores in all areas, and LCQ total scores | Not mentioned | China’s Hubei province |
| | Zhang 2015 [10] | ⑩ | ① + ④ | 60 | 60 | 67/53 | 6–52 | 90 | (4) | Total effective rate | Not mentioned | China’s Liaoning province |
| | Zhang 2017 [11] | ⑩ + ① + ⑤ + ⑥ | ① + ⑤ + ⑥ | 40 | 40 | 48/32 | 18–59 | 28 | (1), (2), (3) | CRP, IL-6, TNF-, total response rate, symptom score (cough, sputum, diaphragmatic fullness) | Not mentioned | China’s Hebei province |
| | Dong 2012 [12] | ⑩ | ① + ② | 49 | 49 | 34/64 | 19–72 | 14 | (4) | Total effective rate, time for improvement of clinical symptoms and signs (dry cough, expectoration, chest tightness, wheezing) | Not mentioned | China Ningxia |
| | Zhang 2019 [13] | ⑩ + ⑨ | ⑨ | 30 | 32 | 32/30 | 1–14 | 14 | (2), (7), (8), (9), (10), (11) | Cough symptom score, (self-modified) TCM syndrome score, effective rate of cough symptom score, effective rate of TCM syndrome score, 3-month recurrence rate, 3-month follow-up score of digestive tract symptoms | 3 months | China’s Fujian province |
| | Lin 2018 [14] | ⑩ | ④ + ⑤ | 31 | 30 | 24/37 | 18–70 | 14 | (2), (10), (12) | Total effective rate, score of cough symptoms, score of comparison of symptoms and signs, total score of symptoms, IgE, safety index | Not mentioned | China’s Fujian province |
| | Shi 2020 [15] | ⑩ + ① | ① | 30 | 30 | 31/41 | 3–12 | 28 | (2), (8), (9) | Total effective rate, IgE, TCM symptom score, 6-month recurrence rate, safety index | 6 months | China's Fujian province |
| | Gong 2019 [16] | ⑩ + ⑨ | ⑨ | 30 | 30 | 39/21 | 62–82 | 30 | Describe | Total effective rate, IgA, IgG, lung function (PEF, FEV1), cough disappearance time, length of hospital stay, adverse reactions | Not mentioned | China’s Sichuan province |
| | Li 2017 [17] | ⑩ + ⑨ | ⑨ | 64 | 64 | 67/61 | 59–82 | 21 | Describe | Total effective rate, duration of asthma, time of disappearance of cough, time of disappearance of pulmonary wheezing, adverse reactions, recurrence rate, adverse reactions | Not mentioned | China’s Guangdong province |
| | Zhu 2016 [18] | ⑩ + ① + ⑤ + ⑥ | ① + ⑤ + ⑥ | 40 | 40 | 48/32 | 18–57 | 28 | (1), (2), (3) | CRP, IL-8, TNF-, total response rate, symptom score (cough, sputum, diaphragmatic fullness), pulmonary function (FVC, FEV1, PEF) | Not mentioned | China’s Hebei province |
|
|
